PolyMedix Receives Phase 2 NIH Grant To Develop A Novel Antimicrobial Defensin Mimetic For Oral Candidiasis
Links shared publicly online about this topic.
- 821total visits
PolyMedix Receives Phase 2 NIH Grant To Develop A Novel Antimicrobial Defensin Mimetic For Oral Candidiasis
PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase
View full resource at medicalnewstoday.com
Tags: Yeast Infection, Candidiasis, Vaginal Infection, Disease and Condition, Drug, Biotech, National Institutes of Health
Most Recently Shared on October 6, 2010 at 3:29 pm By:
PolyMedix Receives Phase 2 NIH Grant To Develop A Novel Antimicrobial Defensin Mimetic For Oral Candidiasis: PolyM... http://mnt.to/f/3KND
Also Shared By:
Advertisement
MNT Infect Diseases
@mnt_diseases
PolyMedix Receives Phase 2 NIH Grant To Develop A Novel Antimicrobial Defensin Mimetic For Oral Candidiasis http://mnt.to/3KND
1 year ago...